Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell (HSC) disorders that can be classified on the basis of genetic, clinical, phenotypic features. Genetic lesions such as JAK2 mutations and BCR-ABL translocation are often mutually exclusive in MPN patients and lead to essential thrombocythemia, polycythemia vera, or myelofibrosis or chronic myeloid leukemia, respectively. Nevertheless, coexistence of these genetic aberrations in the same patient has been reported. Whether these aberrations occur in the same stem cell or a different cell is unclear, but an unstable genome in the HSCs seems to be the common antecedent. In an effort to characterize the underlying genetic events that might contribute to the appearance of more than one MPN in a patient, we studied neoplastic cells from patients with dual MPNs by next-generation sequencing.
| I N T R O D U C T I O N
Myeloproliferative neoplasms (MPNs) are characterized by an expansion of one or more lineages of myeloid stem cells. According to the WHO classification, there are eight different phenotypes of MPNs. 1 Several lines of evidence suggest that genomic instability in the hematopoietic stem cell (HSC) leads to development of molecular lesions that generate the myeloproliferative phenotype. 2 However, the underlying cause of this genomic instability is not well understood. The presence of the BCR-ABL1 fusion gene leads to a chronic myeloid leukemia (CML) phenotype, while mutations in the JAK2 gene are linked to essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF). In addition, exclusive of JAK2, ET, and MF patients can harbor CALR or MPL mutations. 3 These genetic aberrations result in dysregulated tyrosine kinases that generate proliferative signals in the disease-initiating cells. Since these molecular aberrations are usually perceived as mutually exclusive, 4 once one MPN is diagnosed, tests for the other mutation/fusion are rarely performed.
Recently, several case studies have described either concomitant CML and ET/PV/MF or emergence of one of these diseases in patients previously diagnosed with another MPN. [5] [6] [7] [8] [9] In two cases where CML emerged after PV, the BCR-ABL translocation was suggested to be a secondary event in the JAK2-mutated clone. 7, 8 However, others have suggested the mutations may arise in two independent clones. 10 Nevertheless, both these scenarios presuppose an unstable genome that induces multiple changes in a stem cell or favors emergence of other competing clones. In this study, we evaluated the molecular landscape of hematopoietic stem and progenitor cells from patients with Matched buccal swabs were used as the source of normal control DNA for each patient. Patients were identified throughout the study using their study ID assigned during enrollment.
| Clinical data
Clinical characteristics of each consenting patient were extracted from patient charts. Laboratory results (e.g., diagnostic molecular testing), treatment timelines, and drug regimens were compiled from patient charts. Most cases of CML were diagnosed based on classical karyotype and/or FISH. Quantitative molecular diagnosis of BCR-ABLpositive CML to determine response was based on PCR-based testing and was available from some patients for a few time points and the data is presented in International Scale (IS) or as otherwise indicated.
Spleen size measurements were based on palpation unless otherwise stated.
| Integrative high-throughput sequencing and mutation calls
Nucleic acid preparation, sequencing library construction, and highthroughput sequencing were performed using standard protocols in our sequencing laboratory, which adheres to the Clinical Laboratory Improvement Amendments. Paired-end whole-exome libraries from tumor and matched normal DNA were prepared using the Agilent SureSelect human all exon v4 probes (Agilent Technologies, Santa Clara CA). Transcriptome libraries were prepared from total RNA and captured by the Agilent SureSelect human all exon v4 probes. 11 All the libraries were sequenced using the Illumina HiSeq2500 (Illumina, San Diego CA). Aligned exome and transcriptome sequences were analyzed to detect putative somatic mutations, insertions and deletions (indels), copy-number alterations, gene fusions, and gene expression as described previously. Overall, CML was the first MPN diagnosis in two patients, second diagnosis in four patients, and concurrent diagnosis in five patients (data not shown for three) following low level BCR-ABL detection.
| Treatment paradigms for the dual disease patients
Treatment was tailored to the clinically dominant disease in cases of concomitant diagnosis; in the other cases treatment was adjusted to address the second condition. The patients' treatment timelines are summarized in Figure 1A . Each patient's response to the treatment, as measured by spleen size, WBC count, and BCR-ABL levels, is summarized in Figure 1B . An addition or change in therapy was warranted when a patient did not respond to a treatment as indicated by an increase in BCR-ABL transcripts, increase in WBCs, or persistence or increase in splenomegaly. A few of the patients were switched to TKI therapy for CML combined with a JAK inhibitor or another therapy for MF, either given together (Pt2105, dosed with ruxolitinib and imatinib/ dasatinib every day) or in an alternating schedule (Pt1137, alternating schedule of nilotinib 4 days on/1 day off, then ruxolitinib 8 days on/1 day off). Most of these patients demonstrated improved response and safe tolerability with this regimen, potentially endorsing a new The disease diagnosed 1st or is more prominent is listed first.
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| 557 treatment paradigm for dual MPN patients, which can be tested in a carefully designed clinical study.
| Integrative high throughput sequencing of patient samples
We obtained bone marrow and/or peripheral blood samples from 7 of the 8 patients described in this cohort and assessed all genomic alterations in the stem and progenitor cells wherever possible (Table 2) . A sufficient number of HSPCs were enriched by CD34-positive selection from 3 patients, and for the other 4 patients, total bone marrow or peripheral blood mononuclear cells were sequenced. Samples were subjected to integrative sequencing, which includes whole-exome sequencing of the tumor and matched normal sample, transcriptome sequencing, and whole-genome sequencing. The samples for sequencing were obtained at different time points during treatment and stage of disease; therefore, some genetic aberrations at diagnosis were undetectable (Table 2 ). Pt1191 had a BCR-ABL translocation at CML diagnosis, but achieved a major molecular response to dasatinib treatment, which was supported by negative PCR results for BCR-ABL in the sequencing sample ( Figure 2B ). CALR mutations in patients with post-ET MF have only recently been reported, 3 and routine testing was unavailable when patients in this study were first diagnosed with an MPN. Although CALR mutations were not initially detected in Pt2105 during active treatment and stable disease, a length-affecting mutation in exon 9 of the CALR gene was later discovered once the patient's MF symptoms worsened. In most patients, the sequencing results confirmed the molecular diagnostics in the patient charts. For Pt1505, clinical diagnostics did not identify the MPLY591N mutation detected by NGS (10% frequency). The MPLY591N is an atypical weak gain-offunction mutation that increases MPL signaling. 14 In addition to validating clinical findings, NGS detected several additional genetic aberrations in the patients with concomitant MPNs.
We found varying frequencies (1-47%) of mutations in genes involved in epigenetic regulation, including TET2, ASXL1/2, IDH2, SRSF2, and EZH2 (Table 2) , which have known incidences in MF. 15, 16 The 4 (out of 7) patients who harbored at least one of these gene mutations probably have a higher incidence of epigenetic modifications than the <14% incidence in CML (COSMIC data, Supporting Information Table S2 ).
Some patients also harbored oncogenic mutations in N/KRAS, TP53, and BRAF at frequencies varying from 0.5 to 39% ( Table 2 ). The subclonal frequencies of these mutations might indicate clonal evolution of the disease. BRAF mutations found included V600E, a well-established gain- of-function mutation, as well as G469V and D594E, which are two atypical mutations that like V600E, occur within the kinase domain. BRAF D594E has been previously reported in CMML cases. 17 We interrogated the COSMIC database to determine the genes 
| DISCUSSION
This report of eight patients with coexistent ET/PV/MF and CML, along with other reports in the literature underscore that the frequency of this phenomenon is significant. Most often one MPN is diagnosed, precluding further testing for other diseases. Lack of response to therapy is often the reason for alternate/additional diagnoses. Here, we describe the diagnosis and management of patients with coexistent
MPNs. The treatment was tailored to the patient's clinical presentation and tolerance to therapy, and guided by our experience.
We used a whole-genome sequencing approach to understand the pathophysiology of the dual disease phenotype. Our observations suggest that patients with concurrent MPNs acquire either simultaneous or sequential mutations in the HSPC. We therefore propose two models to explain the development of concurrent MPNs at the cellular a Denotes negative finding for BCR-ABL1 fusion gene due to sample timing was when patient was in major molecular response.
level: (1) two independent clones arise from genetically unstable HSPCs and compete with each other and (2) an already mutated HSPC acquires a "second hit". Previous reports from patients with two MPNs suggest that BCR-ABL1 and JAK2 V617F can be present in the same clone of cells or in distinct clones. 6, 7, 9, 10, [18] [19] [20] [21] In some patients (n 5 4) from our cohort, the NGS analysis did not detect a previously identified BCR-ABL1 translocation because patients were in molecular remission at the time of sampling. JAK2 or MPL mutations were detected in these samples after the CML subclone was suppressed. The other interpretation is that the JAK2 mutation precedes BCR-ABL1 translocation and therefore JAK2 persisted after BCR-ABL1 eradication.
Therefore, our data suggest that genetic events that lead to ET/PV/MF arise in the HSPC and CML is a result of a "second hit."
The literature supports that genetic instability in HSPCs is a precondition for MPN initiation. HSPCs from "healthy" individuals, who have no overt disease, can acquire mutations in several genes that might contribute to a preleukemic state, which over time could further destabilize the genome and result in the disease phenotype. 22, 23 These pre-leukemic genes in healthy individuals could provide a competitive advantage to the HSPCs, thus resulting in clonal hematopoiesis. Mutations in epigenetic regulators such as DNMT3A, TET2, and ASXL1 genes occur frequently in these individuals and in patients with MPNs including MF/ET/PV. 16, 24, 25 These epigenetic regulators might contribute to the instability of the HSPC genome. 26, 27 In our studies, mutations in TET2 (n 5 2) and ASXL1 (n 5 3) were found in some patients who were stable or in remission at the time of sampling. We did not detect any DNMT3A mutations, which is consistent with the low frequencies previously reported in MPNs. 15 TET2 loss-of-function mutations in MPNs can worsen the course of JAK2V617F-induced disease and increase the proliferative state of HSCs. 27 ASXL1 was found to be mutated frequently in MF (36%) and rarely in ET and PV. 25 The pathophysiology of loss-of-function ASXL1 mutations is not clear, though some reports have suggested that mutant ASXL1 can collaborate with NRASG12D in promoting myeloid leukemogenesis in mice. 26 Interestingly, ASXL1 mutations along with KRAS or NRAS mutation were found in 2 of the 7 patients with concomitant MPNs. Based on COS-MIC data, TET2 loss-of-function (4%) and ASXL1 loss-of-function (10%) mutations are rarely found in CML, and the biological significance of these mutants in a Ph 1 setting is not yet understood. 24 The relative high frequency of these mutations in our series suggests either dominance of MF with later development of CML, or may explain the presence of two diseases in the same patient.
Novel findings from this small data set include GNAS and BRAF mutations. Although BRAF mutations are frequent in Langerhans cell histiocytosis and hairy cell leukemia (HCL), they are not considered driver mutations in any myeloid neoplasms. 28 Expression of BRAFV600E in murine HSPCs resulted in features consistent with HCL in mice. 29 In our study cohort, 2 of 7 patients had BRAF mutations albeit at low frequency and probably due to clonal evolution. One patient harbored a GNAS hotspot mutation at a relatively high frequency (21%), and this mutation is reported in several gastrointestinal tumors and endocrine tumors. 30 The small sample size of this study does not allow us to conclude whether these mutations are of significance to the dual-disease phenotype.
In conclusion, this is the first report of whole-genome sequencing to determine genomic changes that might contribute to the manifestation of more than one myeloid neoplasm in the same patient. Our data affirms that HSCs accumulate multiple genetic variants, which is a hallmark of patients with hematological malignancies. Identification of one genetic variant did not preclude the presence of another that could drive a phenotypically distinct disease. The data also suggest that the CML in these patients might be a secondary disease arising from underlying genetic instability. Therefore, treatment paradigms for these unusual cases should be tailored to target more than one signaling pathway to sustain remission and improve outcomes of patients.
